CRE Files Data Quality Act Petition on EPA’s Endocrine Disruptor Screening Program
On July10, 2008, the Center for Regulatory Effectiveness filed a Data Quality Act petition on the Amphibian Metamorphosis Assay in EPA's Endocrine Disruptor Screening Program.
CRE’s DQA petition asks EPA to correct the Agency’s statements that the AMA is properly validated and reproducible among different laboratories. CRE’s petition argues that these statements are inaccurate and misleading. External peer review concluded that the AMA has not been validated and is not reproducible.
EPA’s Science Advisory Panel emphasized that the AMA is an “essential” part of the proposed EDSP. Consequently, CRE contends that EPA should not require anyone to use the AMA, or any of the rest of the EDSP, until the scientific community concludes that the AMA and the other EDSP tests are validated and reproducible.
EPA’s initial response to CRE’s petition states that the Agency will respond substantively to the petition within 90 days: i.e., early October 2008.
Click here to read CRE’s petition
Click here to read InsideEPA article on CRE’s petition
®: CRE Regulatory Action of the Week